The software connects Luminex's FDA-cleared Aries PCR-based platform with its multiplex xMap technology-based Magpix system.
With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.
The test is used to identify NSCLC patients for whom treatment with Tarceva in first-line therapy and Tagrisso in second and subsequent lines of therapy may be effective.
Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.
The German molecular diagnostics firm has adjusted its 2015 outlook in response to the FDA letter.
The complementary diagnostic for Bristol-Meyers Squibb's Opdivo is the firm's second test to receive FDA approval this month. The first was for Merck's Keytruda.
The test is for determining whether a patient's tumor expresses the PD-L1 protein and is likely to respond to Merck's drug Keytruda, which the FDA also approved today.
The test was approved for use with Iressa to determine those patients who would benefit by being treated with the drug.
Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.